Abstract
Nitric oxide (NO) deficiency has been implicated in many pathological and physiological processes within the mammalian body providing a plausible biologic basis for the use of NO replacement therapy in these conditions. Exogenous NO sources may hopefully constitute a powerful way to supplement NO when the body cannot generate enough for normal biological functions. This theory has opened up the possibility of designing new drugs that are capable of delivering NO into tissues and the bloodstream in a sustained and controlled manner. This objective has been reached by grafting an organic nitrate structure onto existing molecules with various spacers such as aliphatic or aromatic chain, with different degree of complexity. This approach has led to the synthesis of several new chemical entities in various pharmacological classes, whose profile seems to challenge the parent drug not only on the basis of new pharmacological properties but also on a better toxicological and safety profile. In this article, general aspects on NO and NO donors are reviewed. Major focus is placed upon recent developments of novel NO donors, NO releasing device(s) as well as innovative improvements to conventional NO donors. Several examples are given in some important therapeutic indications such as cardiovascular diseases (NO-aspirin), pain and inflammation (NO-paracetamol), osteoporosis and urinary incontinence (NO flurbiprofen with aliphatic spacer), Alzheimers disease (NO-flurbiprofen with anti-oxidant spacer), respiratory disorders (NO-steroids).
Keywords: Nitric-Oxide Releasing Molecules, iNOs (inducible NO synthase), Rationale, Bronchodilation, NO-flurbiprofen
Current Pharmaceutical Design
Title: Nitric-Oxide Releasing Molecules : A New Class of Drugs with Several Major Indications
Volume: 8 Issue: 3
Author(s): J. L. Burgaud, J. P. Riffaud and P. Del Soldato
Affiliation:
Keywords: Nitric-Oxide Releasing Molecules, iNOs (inducible NO synthase), Rationale, Bronchodilation, NO-flurbiprofen
Abstract: Nitric oxide (NO) deficiency has been implicated in many pathological and physiological processes within the mammalian body providing a plausible biologic basis for the use of NO replacement therapy in these conditions. Exogenous NO sources may hopefully constitute a powerful way to supplement NO when the body cannot generate enough for normal biological functions. This theory has opened up the possibility of designing new drugs that are capable of delivering NO into tissues and the bloodstream in a sustained and controlled manner. This objective has been reached by grafting an organic nitrate structure onto existing molecules with various spacers such as aliphatic or aromatic chain, with different degree of complexity. This approach has led to the synthesis of several new chemical entities in various pharmacological classes, whose profile seems to challenge the parent drug not only on the basis of new pharmacological properties but also on a better toxicological and safety profile. In this article, general aspects on NO and NO donors are reviewed. Major focus is placed upon recent developments of novel NO donors, NO releasing device(s) as well as innovative improvements to conventional NO donors. Several examples are given in some important therapeutic indications such as cardiovascular diseases (NO-aspirin), pain and inflammation (NO-paracetamol), osteoporosis and urinary incontinence (NO flurbiprofen with aliphatic spacer), Alzheimers disease (NO-flurbiprofen with anti-oxidant spacer), respiratory disorders (NO-steroids).
Export Options
About this article
Cite this article as:
Burgaud L. J., Riffaud P. J. and Soldato Del P., Nitric-Oxide Releasing Molecules : A New Class of Drugs with Several Major Indications, Current Pharmaceutical Design 2002; 8 (3) . https://dx.doi.org/10.2174/1381612023396357
DOI https://dx.doi.org/10.2174/1381612023396357 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Patent Selections
Recent Patents on DNA & Gene Sequences Update on Childhood Brucellosis
Recent Patents on Anti-Infective Drug Discovery The Association between Polygenic Hazard and Markers of Alzheimer’s Disease Following Stratification for APOE Genotype
Current Alzheimer Research Anatomical Correlates of the Neuropsychiatric Symptoms in Alzheimer’s Disease
Current Alzheimer Research Opioid Use Disorders in Adolescents: A Review of Prevalence, Problems, Clinical Features and Treatment Options
Adolescent Psychiatry Rho Kinase (ROCK) Inhibitors and Their Application to Inflammatory Disorders
Current Topics in Medicinal Chemistry Biochemical Micro-Techniques in the Diagnosis and Classification of Amyloidosis
Current Pharmaceutical Analysis Role of Resveratrol and its Analogues in the Treatment of Neurodegenerative Diseases: Focus on Recent Discoveries
CNS & Neurological Disorders - Drug Targets Risk and Protective Effects of the Complexin-2 Gene and Gene-Environment Interactions in Schizophrenia
Recent Advances in DNA & Gene Sequences (Discontinued) Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
Current Medicinal Chemistry Block Copolymers for Drug Delivery Nano Systems (DDnSs)
Current Medicinal Chemistry Novel Drugs Affecting Tau Behavior in the Treatment of Alzheimers Disease and Tauopathies
Current Alzheimer Research Meet Our Editorial Board Member
Current Pharmaceutical Design Systems Biology Approaches and Metabolomics for Understanding Japanese Traditional Kampo Medicine
Current Pharmacogenomics and Personalized Medicine Commentary: Obstacles to the Discovery of Medicines for Psychiatric Disorders in Modern Times<sup>§</sup>
CNS & Neurological Disorders - Drug Targets Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Current Diabetes Reviews Neuroprotection of Rotenone-Induced Parkinsonism by Ursolic Acid in PD Mouse Model
CNS & Neurological Disorders - Drug Targets Aberrant Expression of MicroRNAs in B-cell Lymphomas
MicroRNA Free Area of the Spinal Canal and Torg’s Ratio in Acute Cervical Trauma and Degenerative Disease: MANCOVA and Correlational Analyses
Current Medical Imaging